The US Food and Drug Administration (FDA) has granted 510 (k) clearance for BlueWind Medical, Ltd.’s enhanced Revi® implantable tibial neuromodulator for treatment of urgency urinary incontinence (UUI ...

PARK CITY, Utah--(BUSINESS WIRE)--BlueWind Medical, Ltd., a leader in implantable Tibial NeuroModulation (iTNM) and the developer of the Revi® System, today announced that new two-year data from its ...

The data presented today builds on an extensive body of evidence supporting Revi as an intervention that restores quality of life for many patients.” About Urge Urinary Incontinence (UUI) and Quality ...

Enhanced wearable builds on Revi’s strong clinical evidence, meaningful symptom relief, and exceptionally high patient satisfaction. BlueWind Medical, Ltd., a leader in implantable Tibial ...

Participants now being recruited for RESTORE study to expand the evidence base for Revi, a minimally invasive, FDA-authorized, patient-centric tibial neuromodulation therapy PARK CITY, Utah, Feb. 28, ...

The FDA has granted a de novo marketing request for the Revi System for tibial neuromodulation to treat urinary incontinence with or without urinary urgency, BlueWind Medical announced on Thursday.

Revi is a patient-centric solution that empowers patients and redefines the treatment of urge urinary incontinence in a minimally invasive, approachable outpatient procedure PARK CITY, Utah, March 27, ...

The deal would set up Boston Scientific to compete directly with Medtronic in the market for neuromodulation devices that ...

Enhanced wearable builds on Revi’s strong clinical evidence, meaningful symptom relief, and exceptionally high patient satisfaction. SALT LAKE CITY, December 16, 2025--(BUSINESS WIRE)--BlueWind ...